Cobalis gets positive Phase III results on PreHistin

Anti-allergy specialist Cobalis announced that data from its Phase III clinical trial show that preseasonal treatment with PreHistin, its flagship anti-allergy medication, clearly reduced allergy symptoms. The study showed that patients using PreHistin had "significant" reduction in perceived symptoms. The results include only patient-reported data; the company expects to announce analysis of data from clinical exams and blood samples within six weeks.

- read this press release for more